Hub : Traits :

Relative age voice broke

403 significantly associated models · 34 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 199754486 200391561 1 1 3.7e-08 6.9e-10 1.7e-05 51 NR5A2
2 4 94527983 95955095 1 1 2.0e-08 4.1e-08 1.0e+00 100 HPGDS
3 6 99324687 100719911 1 1 3.5e-08 1.6e-08 5.6e-04 63 RP1-199J3.5
4 6 104478130 106230491 2 1 1.6e-21 1.7e-32 7.2e-13 64 LIN28B
5 10 4716018 5229091 1 1 2.6e-07 1.8e-06 4.6e-01 98 AKR1C2
6 10 116155718 118404700 1 1 1.1e-07 2.6e-04 3.5e-01 94 ATRNL1
7 11 122058476 123525464 1 2 2.7e-10 1.2e-10 1.0e+00 100 C11orf63
8 15 60397836 60938816 1 1 8.9e-08 1.2e-08 6.5e-03 77 ANXA2
9 15 88358250 89773505 1 1 9.0e-08 7.1e-08 6.1e-02 88 DET1
10 16 13697975 14759768 1 1 5.4e-08 8.8e-18 1.9e-11 39 RP11-65J21.3
11 16 89189472 90172696 2 2 4.6e-08 1.9e-06 2.7e-01 95 DPEP1 SPIRE2
12 17 42607368 45796313 20 1 3.3e-15 1.1e-13 1.1e-01 95 LRRC37A
13 20 33197489 34697305 1 1 2.2e-07 1.6e-06 8.2e-01 100 UQCC1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Depressed Affect (Nagel 2018) 3.69 2 1 2.2 0.00 1.0e+00 LIN28B LRRC37A
Neuroticism (Nagel 2018) 4.23 2 1 2.2 0.00 1.0e+00 LIN28B LRRC37A
Schizophrenia (2018) 1.79 1 0 0.0 0.00 1.0e+00 LIN28B
Worry (Nagel 2018) 2.76 1 1 2.2 0.00 1.0e+00 LRRC37A
Breast Cancer 1.33 1 0 0.0 0.00 1.0e+00 LRRC37A
Ovarian Cancer 3.20 1 1 2.2 0.00 1.0e+00 LRRC37A
Age at First Birth 1.86 1 0 0.0 0.00 1.0e+00 SPIRE2
Mean Putamen Volume 2.91 1 0 0.0 0.00 1.0e+00 LRRC37A
Neuroticism (2016) 1.91 1 0 0.0 0.00 1.0e+00 LRRC37A
Primary Biliary Cirrhosis 2.01 1 0 0.0 0.00 1.0e+00 LRRC37A
Schizophrenia (2014) 2.24 2 0 0.0 0.00 1.0e+00 LIN28B LRRC37A
Blood Eosinophil Count 1.36 1 1 2.2 0.00 1.0e+00 LRRC37A
Blood Platelet Count 0.69 2 2 4.4 0.00 1.0e+00 HPGDS LRRC37A
Blood Red Count 3.76 3 1 2.2 0.00 1.0e+00 LRRC37A NR5A2 SPIRE2
Blood White Count 0.85 2 0 0.0 0.00 1.0e+00 LRRC37A SPIRE2
Heel T-Score 2.19 5 3 6.7 -0.98 5.6e-04 C11orf63 DPEP1 LIN28B LRRC37A SPIRE2
Height 9.22 9 9 20.0 0.26 4.7e-01 AKR1C2 ANXA2 C11orf63 DET1 DPEP1 LIN28B LRRC37A RP11-65J21.3 UQCC1
Waist Hip Ratio (WHR) 4.04 4 3 6.7 0.55 4.5e-01 AKR1C2 LRRC37A NR5A2 UQCC1
Systolic Blood Pressure 1.25 1 1 2.2 0.00 1.0e+00 UQCC1
Lung FEV1/FVC ratio 0.73 1 0 0.0 0.00 1.0e+00 LRRC37A
Lung FVC 5.45 3 3 6.7 0.00 1.0e+00 LIN28B LRRC37A UQCC1
Neuroticism 4.29 3 1 2.2 0.00 1.0e+00 LIN28B LRRC37A SPIRE2
Hair Pigment 131.93 4 4 8.9 0.80 2.0e-01 DPEP1 LRRC37A SPIRE2 UQCC1
Tanning 86.00 3 3 6.7 0.00 1.0e+00 DPEP1 SPIRE2 UQCC1
Hand grip strength (left) 5.23 3 2 4.4 0.00 1.0e+00 LIN28B LRRC37A UQCC1
Number of treatments/medications taken 2.03 1 0 0.0 0.00 1.0e+00 LIN28B
Sensitivity / hurt feelings 4.26 1 1 2.2 0.00 1.0e+00 LRRC37A
Relative age of first facial hair 21.30 11 10 22.2 0.99 2.1e-09 ANXA2 C11orf63 DET1 DPEP1 HPGDS LIN28B LRRC37A RP11-65J21.3 RP1-199J3.5 SPIRE2 UQCC1
Vitamin and mineral supplements 1.47 1 0 0.0 0.00 1.0e+00 LRRC37A
Impedance of leg (right) 2.30 4 1 2.2 -0.02 9.8e-01 DPEP1 LIN28B LRRC37A UQCC1
Leg fat-free mass (left) 5.38 3 2 4.4 0.00 1.0e+00 AKR1C2 LIN28B UQCC1
Trunk fat percentage 2.12 4 0 0.0 -0.52 4.8e-01 C11orf63 DPEP1 LRRC37A SPIRE2
Hand grip strength (right) 5.58 3 2 4.4 0.00 1.0e+00 LIN28B LRRC37A UQCC1
Fed-up feelings 2.22 1 1 2.2 0.00 1.0e+00 LRRC37A
Age when periods started (menarche) 21.74 7 6 13.3 0.97 7.6e-05 ANXA2 ATRNL1 C11orf63 DET1 HPGDS LIN28B RP11-65J21.3
Heel bone mineral density (BMD) T-score, automated (left) 1.58 1 0 0.0 0.00 1.0e+00 LIN28B
Qualifications: CSEs or equivalent 2.35 1 0 0.0 0.00 1.0e+00 LRRC37A
Sitting height 9.37 4 3 6.7 -0.47 5.3e-01 AKR1C2 LRRC37A RP11-65J21.3 UQCC1
Impedance of leg (left) 2.50 4 1 2.2 -0.04 9.6e-01 DPEP1 LIN28B LRRC37A UQCC1
Leg predicted mass (left) 5.37 3 2 4.4 0.00 1.0e+00 AKR1C2 LIN28B UQCC1
Trunk fat mass 2.62 5 2 4.4 0.08 9.0e-01 C11orf63 DPEP1 LIN28B SPIRE2 UQCC1
Nervous feelings 2.61 1 0 0.0 0.00 1.0e+00 LRRC37A
Frequency of tenseness / restlessness in last 2 weeks 2.97 1 1 2.2 0.00 1.0e+00 LRRC37A
Hearing difficulty/problems with background noise 2.32 1 0 0.0 0.00 1.0e+00 LIN28B
Hair/balding pattern: Pattern 2 3.72 1 1 2.2 0.00 1.0e+00 LRRC37A
Had menopause 1.51 1 0 0.0 0.00 1.0e+00 DPEP1
Forced vital capacity (FVC) 3.34 3 2 4.4 0.00 1.0e+00 DPEP1 LRRC37A RP11-65J21.3
Heel bone mineral density (BMD) T-score, automated (right) 1.75 1 0 0.0 0.00 1.0e+00 LIN28B
Ever unenthusiastic/disinterested for a whole week 2.00 1 0 0.0 0.00 1.0e+00 LRRC37A
Neuroticism score 3.83 1 1 2.2 0.00 1.0e+00 LRRC37A
Weight 3.45 4 1 2.2 0.24 7.6e-01 AKR1C2 C11orf63 LIN28B UQCC1
Impedance of arm (right) 2.48 2 1 2.2 0.00 1.0e+00 LIN28B LRRC37A
Trunk fat-free mass 6.32 4 3 6.7 0.20 8.0e-01 AKR1C2 LIN28B RP11-65J21.3 UQCC1
Hip circumference 2.19 1 1 2.2 0.00 1.0e+00 UQCC1
Time employed in main current job 1.89 1 0 0.0 0.00 1.0e+00 LRRC37A
Father's age at death 1.72 1 0 0.0 0.00 1.0e+00 ANXA2
Worrier / anxious feelings 1.78 1 0 0.0 0.00 1.0e+00 LRRC37A
Hair/balding pattern: Pattern 3 6.21 2 1 2.2 0.00 1.0e+00 LRRC37A NR5A2
Number of live births 2.19 1 0 0.0 0.00 1.0e+00 LRRC37A
Forced expiratory volume in 1-second (FEV1) 3.35 3 2 4.4 0.00 1.0e+00 DPEP1 LRRC37A RP11-65J21.3
Qualifications: A levels/AS levels or equivalent 1.07 1 0 0.0 0.00 1.0e+00 UQCC1
Forced expiratory volume in 1-second (FEV1), Best measure 2.72 2 1 2.2 0.00 1.0e+00 LRRC37A RP11-65J21.3
Impedance of arm (left) 2.99 4 2 4.4 -0.14 8.6e-01 LIN28B LRRC37A SPIRE2 UQCC1
Arm fat mass (right) 1.03 1 0 0.0 0.00 1.0e+00 UQCC1
Trunk predicted mass 6.38 4 3 6.7 0.21 7.9e-01 AKR1C2 LIN28B RP11-65J21.3 UQCC1
Standing height 8.84 8 7 15.6 0.28 4.6e-01 AKR1C2 C11orf63 DET1 DPEP1 LIN28B LRRC37A RP11-65J21.3 UQCC1
Hair/balding pattern: Pattern 4 8.47 1 1 2.2 0.00 1.0e+00 LRRC37A
Peak expiratory flow (PEF) 5.29 3 3 6.7 0.00 1.0e+00 LRRC37A RP11-65J21.3 UQCC1
Medication: Paracetamol 2.82 1 1 2.2 0.00 1.0e+00 LRRC37A
Headache pain in last month 2.90 1 1 2.2 0.00 1.0e+00 LRRC37A
Forced vital capacity (FVC), Best measure 3.21 3 2 4.4 0.00 1.0e+00 LRRC37A RP11-65J21.3 UQCC1
Body fat percentage 1.49 2 0 0.0 0.00 1.0e+00 C11orf63 SPIRE2
Leg fat percentage (right) 1.25 1 0 0.0 0.00 1.0e+00 UQCC1
Arm fat-free mass (right) 5.14 3 3 6.7 0.00 1.0e+00 AKR1C2 RP11-65J21.3 UQCC1
Comparative body size at age 10 2.28 2 1 2.2 0.00 1.0e+00 C11orf63 LIN28B
Qualifications: College or University degree 1.83 2 1 2.2 0.00 1.0e+00 HPGDS LRRC37A
Medication for pain relief, constipation, heartburn 2.24 1 1 2.2 0.00 1.0e+00 LRRC37A
Neck or shoulder pain in last month 1.74 1 0 0.0 0.00 1.0e+00 SPIRE2
Whole body fat mass 1.77 3 0 0.0 0.00 1.0e+00 C11orf63 DPEP1 UQCC1
Arm predicted mass (right) 5.16 3 3 6.7 0.00 1.0e+00 AKR1C2 RP11-65J21.3 UQCC1
Pulse rate, automated reading 0.90 1 0 0.0 0.00 1.0e+00 RP1-199J3.5
Alcohol intake frequency. 1.84 1 1 2.2 0.00 1.0e+00 LRRC37A
Comparative height size at age 10 5.88 3 1 2.2 0.00 1.0e+00 LRRC37A RP1-199J3.5 UQCC1
Supplements: Vitamin C 1.65 1 0 0.0 0.00 1.0e+00 LRRC37A
Knee pain experienced in last month 2.83 1 1 2.2 0.00 1.0e+00 UQCC1
Forced expiratory volume in 1-second (FEV1), predicted 6.69 4 3 6.7 0.83 1.7e-01 AKR1C2 C11orf63 LIN28B UQCC1
Whole body fat-free mass 6.05 4 3 6.7 0.17 8.3e-01 AKR1C2 LIN28B RP11-65J21.3 UQCC1
Leg fat-free mass (right) 5.53 3 2 4.4 0.00 1.0e+00 AKR1C2 LIN28B UQCC1
Handedness (chirality/laterality): Left-handed 1.77 1 0 0.0 0.00 1.0e+00 LRRC37A
Mood swings 3.55 1 1 2.2 0.00 1.0e+00 LRRC37A
Loneliness, isolation 1.58 1 0 0.0 0.00 1.0e+00 LRRC37A
Friendships satisfaction 2.05 1 0 0.0 0.00 1.0e+00 RP11-65J21.3
Mouth/teeth dental problems: Mouth ulcers 2.68 1 1 2.2 0.00 1.0e+00 LRRC37A
Forced expiratory volume in 1-second (FEV1), predicted percentage 3.42 2 1 2.2 0.00 1.0e+00 LRRC37A UQCC1
Whole body water mass 5.89 4 3 6.7 0.16 8.4e-01 AKR1C2 LIN28B RP11-65J21.3 UQCC1
Leg predicted mass (right) 5.52 3 2 4.4 0.00 1.0e+00 AKR1C2 LIN28B UQCC1
Arm fat mass (left) 1.08 1 0 0.0 0.00 1.0e+00 UQCC1
Average weekly champagne plus white wine intake 1.88 1 0 0.0 0.00 1.0e+00 LRRC37A
Miserableness 2.41 1 1 2.2 0.00 1.0e+00 LRRC37A
Guilty feelings 3.05 2 1 2.2 0.00 1.0e+00 LIN28B LRRC37A
Medication: Paracetamol 2.49 1 1 2.2 0.00 1.0e+00 LRRC37A
Basal metabolic rate 5.45 4 2 4.4 0.15 8.5e-01 AKR1C2 LIN28B RP11-65J21.3 UQCC1
Leg fat percentage (left) 1.33 1 0 0.0 0.00 1.0e+00 UQCC1
Arm fat-free mass (left) 5.10 3 2 4.4 0.00 1.0e+00 AKR1C2 RP11-65J21.3 UQCC1
Number of operations (self-reported) 2.12 1 0 0.0 0.00 1.0e+00 LIN28B
Irritability 2.82 1 1 2.2 0.00 1.0e+00 LRRC37A
Myopia 1.49 1 0 0.0 0.00 1.0e+00 LRRC37A
Basal cell carcinoma (self-reported) 3.93 2 2 4.4 0.00 1.0e+00 DPEP1 SPIRE2
Impedance of whole body 2.74 5 3 6.7 -0.15 8.2e-01 DPEP1 LIN28B LRRC37A SPIRE2 UQCC1
Arm predicted mass (left) 5.16 3 3 6.7 0.00 1.0e+00 AKR1C2 RP11-65J21.3 UQCC1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 7 0.201 1.6
GTEx Adipose Visceral Omentum 6 0.295 1.7
GTEx Adrenal Gland 5 0.343 1.6
GTEx Artery Aorta 8 0.269 1.6
GTEx Artery Coronary 9 0.761 1.9
GTEx Artery Tibial 5 0.133 1.5
GTEx Brain Caudate basal ganglia 5 0.543 1.7
GTEx Brain Cerebellar Hemisphere 7 0.470 1.7
GTEx Brain Cerebellum 6 0.303 1.7
GTEx Brain Cortex 7 0.676 1.8
GTEx Brain Frontal Cortex BA9 5 0.541 1.9
GTEx Brain Hippocampus 5 0.954 2.0
GTEx Brain Hypothalamus 5 0.847 1.9
GTEx Brain Nucleus accumbens basal ganglia 7 0.809 1.8
GTEx Brain Putamen basal ganglia 5 0.801 1.8
GTEx Breast Mammary Tissue 7 0.355 1.6
GTEx Breast Mammary Tissue (Male) 8 0.671 1.7
GTEx Breast Mammary Tissue (Female) 7 0.426 1.8
GTEx Cells EBV-transformed lymphocytes 9 0.632 1.9
GTEx Cells Transformed fibroblasts 10 0.238 1.5
GTEx Colon Sigmoid 7 0.479 1.7
GTEx Colon Transverse 8 0.388 1.7
GTEx Esophagus Gastroesophageal Junction 7 0.484 1.7
GTEx Esophagus Mucosa 10 0.301 1.6
GTEx Esophagus Muscularis 9 0.278 1.6
GTEx Heart Atrial Appendage 7 0.443 1.7
GTEx Heart Left Ventricle 6 0.392 1.7
GTEx Liver 4 0.558 1.6
GTEx Lung 10 0.348 1.6
GTEx Muscle Skeletal 9 0.311 1.5
GTEx Nerve Tibial 8 0.185 1.6
GTEx Ovary 6 0.661 1.9
GTEx Pancreas 9 0.551 1.7
GTEx Pituitary 5 0.448 1.7
GTEx Prostate 5 0.599 1.7
GTEx Skin Not Sun Exposed Suprapubic 8 0.325 1.6
GTEx Skin Sun Exposed Lower leg 9 0.247 1.5
GTEx Small Intestine Terminal Ileum 4 0.868 1.9
GTEx Spleen 5 0.354 1.6
GTEx Stomach 7 0.481 1.7
GTEx Testis 11 0.349 1.6
GTEx Thyroid 12 0.300 1.6
GTEx Uterus 6 1.058 1.9
GTEx Vagina 5 0.787 1.7
GTEx Whole Blood 5 0.251 1.5
METSIM Adipose 1 0.022 1.4
NTR Blood 3 0.125 1.4
ROSMAP Brain Pre-frontal Cortex 3 0.068 1.5
YFS Blood 1 0.022 1.4
CommonMind Brain Pre-frontal Cortex 4 0.074 1.4
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.4
The Cancer Genome Atlas Breast Invasive Carcinoma 5 0.113 1.4
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.273 1.4
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.4
The Cancer Genome Atlas Esophageal Carcinoma 3 0.438 1.6
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.391 1.5
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 2 0.073 1.4
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 4 0.098 1.4
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.5
The Cancer Genome Atlas Brain Lower Grade Glioma 4 0.093 1.4
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.4
The Cancer Genome Atlas Lung Adenocarcinoma 4 0.136 1.4
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 4 0.160 1.4
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 4 0.251 1.4
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.120 1.4
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 3 0.226 1.5
The Cancer Genome Atlas Prostate Adenocarcinoma 9 0.195 1.5
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.289 1.5
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 1.5
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.3
The Cancer Genome Atlas Stomach Adenocarcinoma 4 0.238 1.5
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.4
The Cancer Genome Atlas Thyroid Carcinoma 4 0.078 1.4
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.394 1.5